Declaration of Competing Interest statements were not included in the published version of the following articles that appeared in previous issues of Contemporary Clinical Trials Communications.
The appropriate Declaration/Competing Interest statements, provided by the Authors, are included below.
-
1.
“Intestinal-level anti-inflammatory bioactivities of catechin-rich green tea: Rationale, design, and methods of a double-blind, randomized, placebo-controlled crossover trial in metabolic syndrome and healthy adults” [Contemporary Clinical Trials Communications, 2019; 17: 100495] https://doi.org/10.1016/j.conctc.2019.100495
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
2.
“Trauma Management Therapy and Prolonged Exposure Therapy for PTSD in an active duty sample: Design and methodology of a randomized clinical trial” [Contemporary Clinical Trials Communications, 2019; 17: 100491] https://doi.org/10.1016/j.conctc.2019.100491
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
3.
“Virtual reality for pain management in patients with heart failure: Study rationale and design” [Contemporary Clinical Trials Communications, 2019; 16: 100470] https://doi.org/10.1016/j.conctc.2019.100470
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
4.
“Recruitment and retention of families interested in a parent-based pediatric obesity intervention” [Contemporary Clinical Trials Communications, 2019; 16: 100467] https://doi.org/10.1016/j.conctc.2019.100467
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
5.
“2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy” [Contemporary Clinical Trials Communications, 2019; 16: 100461] https://doi.org/10.1016/j.conctc.2019.100461
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
6.
“Design of a novel digital intervention to promote healthy weight management among postpartum African American women” [Contemporary Clinical Trials Communications, 2019; 16: 100460] https://doi.org/10.1016/j.conctc.2019.100460
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
7.
“Integrating smartphone technology, social support and the outdoor built environment to promote community-based aerobic and resistance-based physical activity: Rationale and study protocol for the ‘ecofit’ randomized controlled trial” [Contemporary Clinical Trials Communications, 2019; 16: 100457] https://doi.org/10.1016/j.conctc.2019.100457
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
8.
“Qualitative analysis of COACH: A community-based behavioral intervention to reduce obesity health disparities within a marginalized community” [Contemporary Clinical Trials Communications, 2019; 16: 100452] https://doi.org/10.1016/j.conctc.2019.100452
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
9.
“Statistical considerations for testing an AI algorithm used for prescreening lung CT images” [Contemporary Clinical Trials Communications, 2019; 16: 100434] https://doi.org/10.1016/j.conctc.2019.100434
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
10.
“Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention” [Contemporary Clinical Trials Communications, 2019; 16: 100433] https://doi.org/10.1016/j.conctc.2019.100433
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
11.
“Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression” [Contemporary Clinical Trials Communications, 2019; 16: 100432] https://doi.org/10.1016/j.conctc.2019.100432
Declaration of competing interest: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Sanjay Mathew has served as a consultant to Allergan, Alkermes, Bracket, Clexio Biosciences, Janssen, Perception Neurosciences, and Sage Therapeutics. He has served as a co-investigator for clinical trials funded by NeuroRx and Janssen and has received research support from Biohaven Pharmaceuticals and VistaGen Therapeutics. Dr. Marijn Lijffijt has served as principal investigator for trials funded by NeuroRx and Vistagen Therapeutics.
-
12.
“A descriptive research: Exclusion from submitted clinical data package in the review process of new drug approval due to GCP violation in Japan” [Contemporary Clinical Trials Communications, 2019; 15: 100416] https://doi.org/10.1016/j.conctc.2019.100416
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
-
13.
“Ultrafiltration-profiled hemodialysis to reduce dialysis-related cardiovascular stress: Study protocol for a randomized controlled trial” [Contemporary Clinical Trials Communications, 2019; 15: 100415] https://doi.org/10.1016/j.conctc.2019.100415
Declaration of competing interest: In the last 3 years, JEF has received speaking honoraria from American Renal Associates, the American Society of Nephrology, Dialysis Clinic, Inc., the National Kidney Foundation, and multiple universities. JEF is on the medical advisory board of NxStage Medical, Inc. and has received consulting fees from Fresenius Medical Care, North America and AstraZeneca. In the last 3 years, MMA has received investigator-initiated research funding from the Renal Research Institute, a subsidiary of Fresenius Medical Care, North America and honoraria from the International Society of Nephrology. The remaining authors have no competing interests.
-
14.
“Efficacy of smoking cessation with varenicline plus counselling for e-cigarettes users (VAREVAPE): A protocol for a randomized controlled trial” [Contemporary Clinical Trials Communications, 2019; 15: 100412] https://doi.org/10.1016/j.conctc.2019.100412
Declaration of competing interest: “The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: PC is fixed-term researcher at University of Catania, Italy and won the 2015 unrestricted grant from Pfizer,GRAND, Global Research Award for Nicotine Dependence, that as declared in the text support this study. MM is fixed-term researcher at Centro per la Prevenzione e Cura del Tabagismo, University of Catania.
In relation to his work in the area of tobacco control and respiratory diseases, P has received lecture fees and research funding from Pfizer, Inc., GlaxoSmithKline plc, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. He has also served as a consultant for Pfizer, Inc., Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, NeuroSearch A/S, Boehringer Ingelheim, Duska Therapeutics, Forest Laboratories, ECITA (Electronic Cigarette Industry Trade Association, in the UK), and Health Diplomat (consulting company that delivers solutions to global health problems with special emphasis on harm minimization). Lecture fees from a number of European EC industry and trade associations (including Fédération Interprofessionnelle de la VAPE in France and Federazione Italiana Esercenti Svapo Elettronico in Italy) were directly donated to vaper advocacy no-profit organizations. He is currently Head of the European Technical Committee for standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4). He is also founder of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from the Foundation for a Smoke Free World to support 8 independent investigator-initiated research projects on tobacco harm reduction, and scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti- Smoking League). The other authors have no conflict of interests to declare.
-
15.
“Recruitment challenges in stroke neurorecovery clinical trials” [Contemporary Clinical Trials Communications, 2019; 15: 100404] https://doi.org/10.1016/j.conctc.2019.100404
Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.